News release
From:
The University of Queensland
New evidence has emerged showing that diabetes developed during pregnancy is likely an early manifestation of type 2 diabetes, triggered by the stresses pregnancy places on the body.
In the largest study of its kind, University of Queensland researchers collaborated with the Genetics of Diabetes In Pregnancy (GenDIP) Consortium to analysedata from more than 38,000 women with gestational diabetes and 776,000 without the condition, finding significant genetic similarities between the 2 conditions.
PhD candidate Caroline Brito Nunes at UQ’s Institute for Molecular Bioscience said the research identified 37 genetic variants associated with gestational diabetes, 7 of which had not been previously reported.
“Almost all of these genetic variants overlapped with those linked to type 2 diabetes,” Ms Brito Nunes said.
“We also discovered that some of these variants appear to have stronger effects on diabetes specifically during pregnancy, and found evidence that genetic effects might differ across populations.”
Gestational diabetes affects about 14 per cent of pregnancies and can lead to serious complications including overly large babies, obstructed labour, preterm deliveries, and health risks for both mother and child.
Women who have had gestational diabetes face an 8 to 10-fold increased risk of developing type 2 diabetes later in life, with environmental factors including obesity also playing a part.
Professor David Evans said as gestational and type 2 diabetes were becoming more common and straining health systems across the world, greater understanding of the conditions was needed.
“A key question in the field has been: do they actually represent different conditions or is it the same underlying disease and just the stresses of pregnancy making type 2 diabetes manifest a bit earlier?” Professor Evans said.
“This work has shown that to a large extent they are genetically very similar, with a small genetic component that may be pregnancy specific.”
The study included people from European, East Asian, South Asian, African and Hispanic backgrounds, making it the most diverse genetic study of gestational diabetes to date.
Dr Gunn-Helen Moen said a much larger study with millions of participants is already underway to better understand the genetic drivers and include more diverse populations.
“Our study has identified evidence of genuine ancestry-related differences, and this is something that we will examine further in our larger study,” Dr Moen said.
The study is published in Nature Communications.
Journal/
conference:
Nature Communications
Organisation/s:
The University of Queensland
Funder:
G.H.M. discloses support for the research and publication of this work from the Australian Research Council (DE220101226) and the Research Council of Norway (325640).
D.M.E. discloses support for the research of this work from the National Health and Medical Research Council (2017942).
S.L. discloses support for the research of this work from the National Natural Science Foundation of China (32470642, 31900487), the Guangdong Natural Science Foundation (2022B1515120080), and the Shenzhen Science and Technology Program (20220818100717002).
S.E.S. discloses support for the research of this work from the Novo Nordisk Foundation (NNF18CC0033668, NNF18CC0034900, NNF23SA0084103).
S.K. and J.C. disclose support for the research of this work from the National Human Genome Research Institute (U01HG011723).
S.M. discloses support for the research of this work from the Programa Nicolas Monardes del Servicio Andaluz de Salud, Junta de Andalucia, Spain (RC-0008-2021).
M.M.-V. discloses support for the research of this work from the Instituto de Salud Carlos III (JR20-00040).
D.A.L., M.C.B., and N.M. disclose support for the research of this work from the University of Bristol and UK Medical Research Council (MC_UU_00032/5), the British Heart Foundation (AA/18/7/34219, CH/F/20/90003), and the European Research Council (101021566).
J.R. discloses support for the research of this work from the European Union's Horizon 2020 (874739).
E.K. discloses support for the research of this work from the Research Council of Finland, and the Päivikki and Sakari Sohlberg Foundation.
M.V. discloses support for the research of this work from the Foundation for Diabetes Research, Yrjö Jahnsson Foundation, Signe and Ane Gyllenberg Foundation, Suorsa Foundation, and The Finnish Foundation for Cardiovascular Research.
L.B. discloses support for the research of this work from the Fonds de recherche du Québec – Santé (FRQS).
P.É.J. discloses support for the research of this work from the Fonds de recherche du Québec – Santé (FRQS).
A.H.C., R.N.B., and R.M.F. disclose support for the research of this work from the Wellcome Trust (WT220390).
A.E.H. discloses support for the research of this work from the National Institute for Health and Care Research (NIHR).
M.V. discloses support for the research of this work from the Research Council of Norway (301178) and the University of Bergen.
S.J. discloses support for the research of this work from Helse Vest (912250, F-12144), the Novo Nordisk Foundation (NNF19OC0057445), and the Research Council of Norway (315599).
P.R.N. discloses support for the research of this work from the European Research Council (293574), Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation (TMS2022TMT01), the Research Council of Norway (240413), the Novo Nordisk Foundation (NNF18OC0054741), the University of Bergen, and the Western Norway Regional Health Authority.
A.E. discloses support for the research of this work from the Sarnoff Cardiovascular Research Foundation.
E.W. discloses support for the research of this work from The Academy of Finland (352796).
S.S., V.K., and A.H. disclose support for the research of this work from the European Union under Horizon Europe (101137146, 101137317, 101080250, 101080465, 101057739) and Horizon 2020 (848158, 356888), and the Research Council of Finland (336449, 356888).
A.P.M. discloses support for the research of this work from the Medical Research Council (MR/W029626/1), Versus Arthritis (21754), and the NIHR Manchester Biomedical Research Centre.
L.C. discloses support for the research of this work from the European Union's Horizon 2020 (874739).